6-bromo-N-(6-methoxypyridin-3-yl)-2-morpholinopyrimidin-4-amine | 1254697-48-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 6-bromo-N-(6-methoxypyridin-3-yl)-2-morpholinopyrimidin-4-amine
• CAS: 1254697-48-7
• 化学式: C₁₄H₁₆BrN₅O₂
• 分子量: 366.217
• InChiKey: UKLWUAZJZFIFOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.22
• 重原子数：
  22.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  72.4
• 氢给体数：
  1.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  2-氨基嘧啶-5-硼酸频哪酯 、 6-bromo-N-(6-methoxypyridin-3-yl)-2-morpholinopyrimidin-4-amine 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 0.17h， 生成 N6-(6-methoxypyridin-3-yl)-2-morpholino-4,5'-bipyrimidine-2',6-diamine
  参考文献：
  名称：

  Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors

  摘要：

  Phospoinositide-3-kinases (PI3K) are important oncology targets due to the deregulation of this signaling pathway in a wide variety of human cancers. series of 2 morpholino, 4-substituted, 6-(3-hydroxyphenyl) pyrimidines have been reported as potent inhibitors of PI3Ks. Herein, we describe the structure guided optimization of these,pyrimidines with a focus on replacing the phenol moiety, while maintaining potent target inhibition and improving in vivo properties A series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines, which potently inhibit PI3K, were discovered,Within-this series a compound, 17, Was identified with suitable pharmacokinetic (PK) properties, which allowed for the establishment of a PI3K PK/pharmacodynamic-efficacy relationship as determined by in vivo inhibition of AKT(Ser473) phosphorylation and tumor growth inhibition in a mouse A2780 tumor xenograft model.

  DOI：

  10.1021/ml1001932
• 作为产物：
  描述：

  吗啉 、 5-氨基-2-甲氧基吡啶 、 2,4,6-三溴嘧啶 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 4.0h， 生成 6-bromo-N-(6-methoxypyridin-3-yl)-2-morpholinopyrimidin-4-amine
  参考文献：
  名称：

  Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors

  摘要：

  Phospoinositide-3-kinases (PI3K) are important oncology targets due to the deregulation of this signaling pathway in a wide variety of human cancers. series of 2 morpholino, 4-substituted, 6-(3-hydroxyphenyl) pyrimidines have been reported as potent inhibitors of PI3Ks. Herein, we describe the structure guided optimization of these,pyrimidines with a focus on replacing the phenol moiety, while maintaining potent target inhibition and improving in vivo properties A series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines, which potently inhibit PI3K, were discovered,Within-this series a compound, 17, Was identified with suitable pharmacokinetic (PK) properties, which allowed for the establishment of a PI3K PK/pharmacodynamic-efficacy relationship as determined by in vivo inhibition of AKT(Ser473) phosphorylation and tumor growth inhibition in a mouse A2780 tumor xenograft model.

  DOI：

  10.1021/ml1001932

文献信息

• Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
  作者：Matthew T. Burger、Sabina Pecchi、Allan Wagman、Zhi-Jie Ni、Mark Knapp、Thomas Hendrickson、Gordana Atallah、Keith Pfister、Yanchen Zhang、Sarah Bartulis、Kelly Frazier、Simon Ng、Aaron Smith、Joelle Verhagen、Joshua Haznedar、Kay Huh、Ed Iwanowicz、Xiaohua Xin、Daniel Menezes、Hanne Merritt、Isabelle Lee、Marion Wiesmann、Susan Kaufman、Kenneth Crawford、Michael Chin、Dirksen Bussiere、Kevin Shoemaker、Isabel Zaror、Sauveur-Michel Maira、Charles F. Voliva

  DOI：10.1021/ml200156t

  日期：2011.10.13

  Phosphoinositide-3-kinases (PI3Ks) are important oncology targets due to the deregulation of this signaling pathway in a wide variety of human cancers. Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocydic pyrirnidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent. The resulting 2,4-bismorpholino 6-heterocyclic pyrirnidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma). These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clinical trials for the treatment of cancer.